Alcaide, JuliaDelgado, MayteLegerén, MartaJurado, José MiguelBlancas, IsabelPereda, TeresaLópez, JorgeGarrido, MargaritaSánchez, María JGarcía, José LRueda, Antonio2017-05-022017-05-022016-11Alcaide J, Delgado M, Legerén M, Jurado JM, Blancas I, Pereda T, et al. Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. Oncol Lett. 2016 ; 12(5):3127-31341792-1074http://hdl.handle.net/10668/2623Journal Article;Aflibercept is a recombinant fusion protein that acts by inhibiting tumoural angiogenesis. Efficacy data obtained in the VELOUR randomised study has contributed to the approval of aflibercept as a second-line metastatic colorectal cancer (mCRC) treatment following an oxaliplatin-based regimen. The present study reports a case series of five patients with mCRC, who were treated in two centres since 2011 in the Compassionate Use Program for aflibercept. All patients had a KRAS mutation and previously received palliative fluoropyrimidine-oxaliplatin-based chemotherapy with bevacizumab. A doublet with irinotecan combined with aflibercept was administered until progression of disease. The majority of patients received a greater number of aflibercept cycles than the median reported in the VELOUR study (12 vs. 7 cycles), with manageable and reversible toxicity. The most frequent adverse events observed were diarrhoea, neutropenia, fatigue, proteinuria and hypertension. Most cases obtained a progression-free survival greater than the median reported in the VELOUR study (11 vs. 6.9 months) and, in a subgroup of patients previously treated with bevacizumab, and a median survival time of ~47 months was reached from the initial treatment of the disease. The present study contrasts the efficacy and safety results obtained from the pivotal VELOUR trial, and confirms that aflibercept, used in routine clinical practice outside of the clinical trial environment, is active and well-tolerated following bevacizumab treatment.enMetastatic colorectal cancerAfliberceptAngiogenesisTargeted therapyVEGFVEGFRCamptotecinaNeoplasias colorrectalesEnsayos de Uso compasivoSupervivencia sin enfermedadHumanosHipertensiónMutaciónCompuestos organoplatinosPoliésteresProteinuriaProteínas recombinantes de fusiónReceptores de Factores de crecimiento endotelial vascularMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Alkaloids::CamptothecinMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal NeoplasmsMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Therapies, Investigational::Compassionate Use TrialsMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free SurvivalMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Diseases::Cardiovascular Diseases::Vascular Diseases::HypertensionMedical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::MutationMedical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::NeutropeniaMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Organometallic Compounds::Organoplatinum CompoundsMedical Subject Headings::Chemicals and Drugs::Macromolecular Substances::Polymers::PolyestersMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Urological Manifestations::ProteinuriaMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Recombinant Proteins::Recombinant Fusion ProteinsMedical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases::Receptor Protein-Tyrosine Kinases::Receptors, Vascular Endothelial Growth Factorresearch article27899972open access10.3892/ol.2016.50681792-1074PMC5103908